IMS Biosimilar 2017 - V9 PDF

May 2017
The Impact of Biosimilar

Competition in Europe
Contents
01 Introduction
02 Definitions
03 Four Observatons by QuintilesIMS
09 The country and therapy areas KPIs
09 Epoetin (EPO)
11 Granulocyte colony-stimulating factor (G-CSF)
13 Human growth hormone (HGH)
15 Anti-tumor necrosis factor (Anti-TNF)
18 Fertility (Follitropin alfa)
20 Insulins
23 Reading guide
27 Appendices
27 EMA list of approved Biosimilars
28 Methodology
29 QuintilesIMS source of volume data
30 QuintilesIMS source of price data
The Impact of Biosimilar Competition in Europe Page 2

Introduction
This document sets out to describe the effects on price, volume and market share following the arrival
and presence of biosimilar competition in the European Economic Area (EEA). The report consists of a
set of Key Performance Indicators (KPI’s) to monitor the impact of biosimilars in European markets,
using full year 2016 data.
This report has been prepared by QuintilesIMS at the request of the European Commission services
with initial contributions from EFPIA, Medicines for Europe, and EuropaBio.
The European Medicines Agency (EMA) has a central role in setting the rules for biosimilar submissions,
approving applications, establishing approved indications and monitoring adverse events, and if
necessary issue safety warnings. We have, when appropriate, quoted their information and statements.

Definitions
The report uses some basic terms defined as follows:
• Accessible category: products within the same ATC4 code including the following three product categories:
• Referenced Medicinal Product: Original product, granted market exclusivity at the start of its life, exclusivity
has now expired and the product has been categorised as referenced.
• Non-Referenced Medicinal Product: Original product, granted market exclusivity at the start of its life,
exclusivity has now expired and the product has never been categorised as a Referenced Medicinal
product, or may have been referenced but the referencing biosimilar has not been launched.
• Biosimilar Medicinal Product: Product, granted regulatory approval, demonstrating similarity to the Reference
Medicinal Product in terms of quality characteristics, biological activity, safety and efficacy.
• Non-accessible category: products within the same ATC4 code as the accessible category products, and are
typically second generation products; this category may include products with different dosing schedules and /
or route of administration to those in the accessible category.
• Total market: includes both the Accessible and the Non-accessible product markets.
The KPI’s used in the report focus on price and volume trends
• Launch date: date of first recorded sales of Biosimilar Medicinal Product in the country.
• Price indicators:
• Price: the price level used is gross ex-manufacturer price, which values the product at the level that the
manufacturer sells out, without taking into account rebates or discounts.
• Price evolution: price per Treatment Day (TD) in 2016 versus year before biosimilar entry.
• Volume indicators:
• Volume: volume is measured in Treatment Days (also known as Defined Daily Dose) which is a measure of
the average dose prescribed as defined by the WHO.
• Biosimilar market share: number of biosimilar treatment days as a share of (i) biosimilar + referenced
product(s) volume, (ii) accessible market volume and (iii) total market volume.
• Volume evolution: number of Treatment Days in 2016 versus year before biosimilar entry.
• Volume per capita 2016: number of Treatment Days consumed in 2016 normalised by population size.
• Volume per capita year before biosimilar entrance: number of Treatment Days consumed the year before
the entrance of biosimilars, normalised by population size.
Caveats
The indicators are intended to give a broad overview of the uptake and the implications on price and volume evolution
after introduction of biosimilar medicines. There are differences in perspective between payers, providers, and different
types of manufacturers. In focusing on the payers there are a few key caveats that need to be made when interpreting
the results:
• Pricing and discounts: the report is based on publically available LIST prices. Discounting occurs, especially in
contracting with hospitals and in countries using tenders for biological drug procurement, which can lead to larger
price fluctuations than is visible through the reported QuintilesIMS data.
• Approved indications and efficacy: not all products in a specific product group in the accessible, non-accessible
or total market have the same approved indications and can have differences in efficacy and individual patient
outcomes. Biosimilars normally receive the same indications as the reference products and are inferred to have
similar efficacy.
• Volume estimates: the pack volumes reported are based on QuintilesIMS collected data which may have been
unknowingly impacted by issues such as parallel exporting. The volumes have been converted to daily doses using
the published World Health Organization (WHO) defined daily doses (DDD) which can introduce bias. Consumption
measures are therefore not adjusted for clinical practice guidelines, patient characteristics, indications for which the
molecule is used, or other factors that may result in different volumes utilised on a per patient Treatment Day basis.

Four Observations by QuintilesIMS
1. The entrance of biosimilars increases price competition
1a. Competition drives down price
The rationale behind the introduction of biosimilars Exhibit 1: Total change in price per TD since the
is to increase price competition, an effect of which entrance of biosimilars for each therapy area
is often reduced prices. The six established therapy
areas with biosimilar competition show a consistent Price per TD 2016/
picture of reduced average list prices in European Year before Biosimilar entrance
Economic Area (EEA)Price countries (see Exhibit 1).
per TD 2016/ Biosimilar Biosimilar
Year before Biosimilar entrance and Accessible Total market
The increased competition resulting from biosimilars Reference market
Biosimilar Biosimilar product
entering the market
and affects not just the price of the
Accessible
Reference Total market EPO -31% -33% -27%
market
respective biosimilars reference product, but also the
product
price of the whole product class. It can have almost G-CSF -37% -36% -27%
EPO -31% -33% -27%
as large an impact on the total market price as it has HGH -21% -15% -15%
onG-CSF -37%
the biosimilar/reference -36% -27%
product price. Anti-TNF -13% -13% -10%
HGH -21% -15% -15%
Exhibit 2 shows the three countries where the highest Fertility -6% -5% -4%
Anti-TNF -13% -13% -10%
price reduction of the total market has been achieved. Insulins -3% 1%
-7%
In Fertility -5%
-6% in Portugal,
the case of EPO’s -4% decease
the price
canInsulins
be as much-7% as -66%. -3% 1%
Other countries may also have high price reductions, through non-published discounting. However, such
reductions are not visible in the data in this report. In addition, the highest reduction may not equal the
lowest price. Price per TD 2016 / Price per TD
Year before Biosimilar Year before B
Price per TD 2016 / Price per TD 2016 / Exhibit 2: Countries
entrance with the highest entran
Year before Biosimilar Year before Biosimilar Total market
EPO price reduction G-CSF since Total ma
of the total market
entrance entrance
the entrance of
-66% biosimilars -62%
EPO Total market G-CSF Total market Portugal Romania
Portugal -66% Romania -62% Slovakia -53% Slovakia -61%
Slovakia -53% Slovakia -61% Norway -51% Slovenia -57%
Norway -51% Slovenia -57% HGH Anti-TNF
HGH Anti-TNF Finland -52% Sweden -39%

Finland -52% Sweden -39% Poland -42% Norway -32%
Poland -42% Norway -32% Norway -37% Denmark -24%
Norway -37% Denmark -24%
Fertility Insulins
Fertility Insulins Denmark -24% Finland -18%
Denmark -24% Finland -18% Spain -14% France -5%
Spain -14% France -5% Sweden -10% Ireland -3%
Sweden -10% Ireland -3%

1b. The correlation between biosimilar market share and price is weak
The correlation between biosimilar volume market share of the total market and price reduction of
the total market is weak, as can be seen by the six established biosimilar classes.
For the six classes we can see the same pattern; high savings can be achieved even if the biosimilar
market share is low. Price reduction can be achieved through price regulation interventions and/
or commercial decisions of manufacturers. Even if the biosimilar product does not end up to be the
product sold, it is likely an essential step to generate a more competitive environment, which leads
to lower prices. However, in the long term, low biosimilar uptake could lead to fewer new biosimilars
being developed, reducing the overall competitive pressure.
Exhibit 3: Biosimilar market share in 2016 vs change in price per TD (2016/year before biosimilar
entrance) by country
EPO G-CSF
20%
0% 20% 40% 60% 80% 100%
10%
20%
Change in Price per TD
0%
10%
-10% 0% 10% 20% 30% 40% 50% 60% 70% 80%
0%
-20% -10%
-30% -20%
-40% -30%
-50% -40%
-60% -50%
-60%
-70%
-70%
-80%
Biosimilar Market share TD (2016) Biosimilar Market share TD (2016)
Fertility Anti-TNF
0% 2% 4% 6% 8% 10% 20%
40%
10%
30%
0%
20%
0% 10% 20% 30% 40% 50% 60% 70% 80%
-10%
10%
0% -20%
-10% -30%
-20% -40%
-30% -50%
-40% -60%
HGH Insulins
20%
20%
10%
15%
0%
10%
-10% 0% 10% 20% 30% 40% 50% 60% 70% 80%
5%
-20%
0%
-30%
-5% 0% 1% 1% 2% 2%
-40%
-10%
-50% -15%
-60% -20%
-70% -25%
-80%

1c. The entrance of just one biosimilar in the market can be sufficient to lower the price
In classes with more than one biosimilar, there is a weak correlation between the number of biosimilar
competitors and the change in price of the total market.
In order to achieve savings, there does not have to be competition with multiple biosimilars. However,
in the long term, it may be necessary to have multiple biosimilars in order to achieve the full effect of
competition. This dynamic is very different to small molecule generics, but may differ by class, and
may evolve as we see more competition in newer classes.
Anti-TNF EPO
EPO Exhibit 4: Change in price per TD (2016/year
5 6
5 6 before biosimilar entrance) vs total number
Number of Biosimilars
5
Biosimilars
4
of biosimilars on the market in a country
Biosimilars
5
4 4
34
3 3
of of
23
2
Number
2
Number
12 1
1 1
0 0
-45% -40% -35% -30% -25% -20% -15% -10% -5% 00% -70% -60% -50% -40% -30% -20% -10% 0%
0
0% -70% -60% -50% -40% -30% -20% -10% 0%
Change in Price per TD Change in Price per TD
G-CSF
7
Number of Biosimilars
7 6
6 5
5 4
4 3
3 2
2 1
1 0
0 -70% -60% -50% -40% -30% -20% -10% 0% 10% 20%
0% 0% 10% 20%
2. In some therapeutic classes, lowering the price of the referenced product can limit
the market penetration of the biosimilar
For two of the therapeutic classes, anti-TNF and HGH, the same observation can be seen: there is a
correlation between the price reduction of referenced products (after biosimilar entry), and the
biosimilar market share. Therefore the larger the originator’s price cut on the referenced product, the
less impact of biosimilars is seen.
This illustrates that originator competitive pricing strategies can influence the uptake of biosimilars
in some areas. However, reducing originator prices (either because of regulations applied in a country
or competitive originator pricing strategies), could result in biosimilars not entering the market at all,
restricting competition in the market.

Exhibit 5: Change in price of the referenced product(s) (2016/year before biosimilar entrance) vs
biosimilar market share in 2016
HGH
Anti-TNF
80%
Biosimilar Market share TD (2016)

70%
Biosimilar Market share TD (2016)
70%
60%
60%
50%
50%
40%
40%
30% 30%
20% 20%
10% 10%
0% 0%
-40% -30% -20% -10% 0% 10% 20% 30% 40% -60% -50% -40% -30% -20% -10% 0% 10% 20% 30%
-10%
Price change of referenced product after Biosimilar entry Price change of referenced product after Biosimilar entry
3. There is a first to market advantage in biosimilar markets
In those therapy classes where more than one biosimilar has been launched, assessing all biosimilars in
Anti-TNF
each class, the first biosimilar to market usually takes the highest biosimilar market share. Therefore
time to market for biosimilars can impact uptake in the2016
class.
Biosimilar Biosimilar Volume (TD)
time to market share% (average
Where multiple launches occurred in theMarket
same month inall
across a countries)
country, market shares for these products
were assigned to the same rank. For Anti-TNF’s, biosimilars for both etanercept and infliximab were
1st 72%
considered in a country.
2nd 30%
3rd 5%
Exhibit 6: Average biosimilar market share in 2016 across all countries for each biosimilar, according to
4th 0%
their time to market in a country
Anti-TNF EPO
Biosimilar Biosimilar 2016 Volume (TD) Biosimilar Biosimilar 2016 Volume (TD)
time to market share% (average time to market share% (average
Market across all countries) Market across all countries)
1st 72% 1st 73%
2nd 30% 2nd 40%
3rd 5% 3rd 22%
4th 0%
G-CSF
EPO
Biosimilars Biosimilar 2016 Volume (TD)
Biosimilar Biosimilar 2016 Volume (TD) time to market share% (average
time to market share% (average Market across all countries)
Market across all countries)
1st 44%
1st 73%
2nd 37%
2nd 40%
3rd 24%
3rd 22%
G-CSF
4. Biosimilars have the potential to improve patient access of the total market
4a. Lower prices increase patient access
Some level of price-elasticity is expected to be observed for these products. The report however shows
different levels of impact to lowered prices for different countries and different classes.
For most classes, there is a significant increase in consumption since biosimilar entry in countries
which had low starting volumes. There are also some countries which already had high usage of classes
before biosimilar entry, such as Sweden with Anti-TNF’s, which show a significant increase in con-
sumption.
Therefore lowered prices can impact usage, however there are other factors to consider:
• New indications or restriction of indications (for example the EPO safety warnings)
• General economic conditions imposing use restrictions
• Changes in diagnosis and prevalence of diseases
Exhibit 7: Countries with highest change in volume TD (2016/year before biosimilar entrance)
Price per Volume Price per Volume

TD 2016/ TD 2016/ TD/capita TD 2016/ TD 2016/ TD/capita
Year before Year before (Year before Year before Year before (Year before
Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar
Anti-TNF entrance entrance entrance) G-CSF entrance entrance entrance)
Bulgaria -23% 190% 0.10 Romania -62% 2542% 0.02
Slovakia -19% 93% 0.49 Bulgaria -47% 581% 0.02
Sweden -39% 74% 0.94 Slovakia -61% 509% 0.05
Portugal -13% 63% 0.26 Slovenia -57% 178% 0.05
Czech -13% 59% 0.24 Norway -31% 164% 0.07
EPO HGH
Poland -46% 237% 0.03 Romania -31% 152% 0.02
Greece -51% 196% 0.02 Poland -42% 82% 0.04
Italy -10% 39% 0.82 UK -16% 79% 0.04
Czech -32% 36% 0.09 Finland -52% 70% 0.06
Bulgaria -16% 36% 0.23 Czech -25% 68% 0.08

4b. Overall, Biosimilar competition contributes to the increased patient access of the
whole market
Increased competition (an effect of which is often reduced prices) in the market is one of several
drivers of volume growth. Our analysis reports that the increased competition of biosimilars entering
the market has an impact on not just the volume of the directly comparable referenced product, but
also the volume of the whole product class. The total market volume uptake varies significantly by
class in Europe. It must be noted that all products in these therapy areas, including biosimilars, are
contributing to this increased patient access (TD), to varying degrees in each country.
Exhibit 8: Total change in volume per TD since the entrance of biosimilars for each therapy area
Volume per TD
(2016/Yr before BS entrance)
Biosimilar and Biosimilar
Referenced Total
Referenced Accessible
product only markets
product market
G-CSF -74% 122% 63% 58%
HGH -14% 41% 45% 45%
Anti-TNF -10% 19% 19% 26%
Fertility 2% 16% 8% 10%
EPO -37% 66% 4% 7%
Insulins 14% 19% 15% 4%
The experience so far with Biosimilars in Europe illustrates the heterogeneity between biosimilar
products, therapy areas, and countries. There is not just one formula that will work to achieve the
savings potential, but learnings can be taken from all areas.

The country and therapy areas KPIs
Epoetin (EPO)
Epo is a form of human erythropoietin produced by recombinant technology, with the same amino acid
sequence and mechanism of action as endogenous erythropoietin. Its major functions are to promote
the differentiation and development of red blood cells and to initiate the production of haemoglobin,
the molecule within red blood cells that transports oxygen.
Epoetin volume development
60000
Non-accessible Market Medicinal
Products: Aranesp, Mircera
50000
Non Referenced Medicinal Products:
NeoRecormon, Eporatio, Dynepo*
40000
TD per 100,000
Referenced Medicinal Products:

30000 Erypo, Epopen, Epopen
20000
Biosimilar Medicinal Products:
Abseamed, Binocrit, Epoetin Alfa-
Hexal, Retacrit, Silapo
10000
0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Source:
The QuintilesIMS
average for EEAMIDAS December
is not 2016; Total volume
representative development
for any across
individual all European
country whichcountries includedin
is illustrated in the
thestudy
next section. *Dynepo has been withdrawn by the EMA.
Summary of EMA information for approved indications for Epoetin products Patient
type Frequency* Route**
Reduction of
Reference product
allogenic
Non-accessible
Subcutaneous
Non-reference
Anaemia for Preventing transfusion
Intravenous
Paedriatic
Biosimilar
Anaemia for patients with Anaemia in Autologuos exposure in

Chemotherapy Chronic Kidney premature Blood Orthopedic
Adult
Molecule Product patients Disease babies Transfusion surgery

Epopen 3x a week
Erypo 3x a week
3x a week
Epoetin alfa Epogen
3x a week
Abseamed 3x a week
Epoetin Alfa Hexal 3x a week
3x a week
Binocrit
Retacrit
Epoetin zeta 3x a week
Silapo
Epoetin beta NeoRecormon 3x a week
Epoetin theta Eporatio 3x a week
Methoxy
polyethlene Mircera Every 2 weeks
glycol-epotein
beta
Darbepoetin alfa Aranesp Weekly
*Anaemia for patients with Chronic kidney disease ** Subcutaneous injection is typically used for chemotherapy patients. Intravenous injection
is typically used for patients with kidney problems and for patients who are going to donate
their own blood.

EPO
Additional information about Epoetin
In June 2008 EMA recommended updating the product information for Epoetin-containing medicines
with a new warning for their use in cancer patients stating that blood transfusion should be the preferred
method of correcting anaemia. The Agency’s Committee for Medicinal Products for Human Use (CHMP)
had reviewed data from studies that showed an increased risk of tumour progression, venous thrombo-
embolism and shorter overall survival in cancer patients who received Epoetins compared to patients who
did not receive them. It also advised that prescribers take into account patients’ individual circumstances
and preferences when making the decision to use Epoetins. The Committee agreed that there is no
consequence of the new information on the use of Epoetin-containing medicines for the treatment of
anaemia in patients with chronic renal failure.
Selected KPIs to illustrate volume share, price evolution, and volume evolution in selected European countries:
Price per TD (2015/the year before Volume TD (2015/the year before

Market share TD (2015) biosimilar entrance) biosimilar entrance)
Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar Total Biosimilar Biosimilar Total TD/capita TD per capita First
vs vs vs and Accessible market and Accessible market (Yr before BS 2015 Recorded
Reference Accessible Total market Reference market Reference market entrance) Sales of
product market product product Biosimilar
AU 76% 25% 16% -36% -37% -26% -29% -8% -26% 0.95 0.70 2008
BE 2% 1% 1% -1% -1% 0% -14% -10% -5% 0.53 0.50 2014
BU 100% 79% 45% -5% -35% -16% 59% 2% 36% 0.23 0.32 2011
CZ 99% 50% 32% -47% -38% -32% 129% 21% 36% 0.09 0.13 2011
DK 70% 5% 0% -41% -1% -12% -96% -94% -7% 0.49 0.46 2010
FI 100% 60% 10% -42% -36% -22% 1137% -49% 8% 0.34 0.36 2008
FR 45% 26% 10% -33% -33% -32% -3% -24% 4% 0.90 0.93 2009
DE 81% 67% 37% -53% -56% -46% 33% -22% -16% 0.39 0.33 2007
GR* 98% 97% 95% -51% -52% -51% 630% 337% 196% 0.02 0.06 2008
HU 100% 52% 31% -67% -33% -18% -9% -9% -27% 0.38 0.28 2009
IE 91% 8% 3% -32% -30% -19% -32% -56% -30% 0.52 0.36 2008
IT 65% 57% 44% -17% -15% 10% 160% 68% 39% 0.82 1.15 2008
NL 30% 12% 3% -47% -42% -32% -63% -53% -25% 0.58 0.43 2009
NO 87% 44% 4% -55% -51% -51% 16% -55% 11% 0.21 0.23 2008
PL 100% 16% 13% -63% -54% -46% 3327% 338% 237% 0.03 0.09 2009
PT 87% 28% 21% -79% -80% -66% 232% 139% 6% 0.44 0.47 2010
RO 70% 50% 26% -54% -48% -39% 130% -63% -38% 0.29 0.18 2009
SK 100% 73% 58% -60% -58% -53% 361% 67% 11% 0.45 0.50 2010
SL 46% 22% 8% -50% -44% -42% -40% -41% 7% 0.52 0.56 2009
ES 60% 46% 29% -31% -31% -21% 64% 1% -4% 0.70 0.67 2009
SE 94% 51% 20% -20% -31% -45% 44% -12% 23% 0.48 0.58 2008
CH 22% 6% 1% -46% -45% -42% -43% -50% 13% 0.34 0.39 2009
UK 6% 3% 1% -7% -13% -10% 70% -10% 27% 0.24 0.31 2009
EU 62% 45% 25% -31% -33% -27% 66% 4% 7% 0.49 0.53
The following data history is used: PT Hospital (2010-2016), DK (2007-2016), IE Hospital (2006-2016), *Only retail panel is available for Greece.
Prices per TD (total market) have been reduced in almost all markets but to a different degree (0)
to (-66%) due to a combination of factors; the level of competition, to what extent Non- Accessible
Market products (largely differentiated by fewer injections) have been accepted, but also the price
development of referenced and biosimilar medicinal products. The volume development shows that
in several of the markets, the usage is greatly reduced following the 2008 safety warning.

Granulocyte-colony stimulating factor (G-CSF)
G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and
release them into the bloodstream. G-CSF is used prophylactically with certain cancer patients to ac-
celerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens.
G-CSF volume development

5000 Products: Lonquex, Neulasta,
Leucomax, Leukine
4500
4000 Non-referenced Medicinal Products:

Euprotin, Granocyte, Myelostim,
3500 Neutrogin
TD per 100,000
3000
2500
Neupogen
2000
1500 Biosimilar Medicinal Products:

Filgrastim Hexel, Granulokine,
1000 Grasalva, Grastofil, Neukine,
Nivestim, Ratiograstim
500
0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Source: QuintilesIMS MIDAS December 2016; Total volume development across all European countries included in the study
Summary of EMA information for approved indications for G-CSF products
Classification Indication
Severe Chronic
Neutropenia
(SCN) with
Cytotoxic diagnois of
Chemoterapy Neutropenia Bone Marrow Mobilisation of congenital, Neutropenia
Non- Non- associated with induced by Transplantation Peripheral Blood cyclic, or prevention and
Reference Biosimilar reference accessible Febrile induced Acute Myeloid induced Progenitor Cells idiopathic treatment in
Molecule Product product Product Product Product Neutropenia Leukemia Neutropenia (PBPCs) Neutropenia patients with HIV
Neupogen
Filgrastim
Hexal
Granulokine
Filgrastim Grasalva
Grastofil
Neukine
Nivestim
Ratiograstim
Euprotin
Granocyte
Lenograstim
Myelostim
Neutrogin
Lipegfilgrastim Lonquex
Pegfilgrastim Neulasta
Molgramostim Leucomax
Sargramostim Leukine

G-CSF
Additional information about G-CSF
Subcutaneous injection typically used to administer G-CSF daily for 5-7 days, starting 72hrs after
completion of chemotherapy or bone marrow transplantation, with the exception of pegfilgrastim
and lipegfilgrastim which are long acting G-CSF and therefore administered once only at least 24 hrs
after completion of each chemotherapy cycle. GM-CSF (Granulocyte macrophage colony-stimulating
factor) Sargramostim and Molgramostim are given daily, most often as a subcutaneous injection
(under the skin), but can also be given directly into a vein (intravenous, IV).
Selected KPIs to illustrate volume share, price evolution, and volume evolution in selected European
countries:

Market share TD (2016)
biosimilar entrance) biosimilar entrance)
AU 88% 87% 18% -48% -48% -39% 84% 66% 79% 0.05 0.10 2009
BE 3% 3% 0% -28% -27% -10% 3% 4% 27% 0.04 0.06 2011
BU 100% 100% 19% -81% -83% -47% 272% 105% 581% 0.00 0.02 2010
CZ 100% 100% 51% -33% -33% -25% 195% 195% 117% 0.00 0.01 2010
DK 93% 91% 11% -48% -48% -21% -3% -8% 30% 0.04 0.05 2009
FI 98% 97% 16% -32% -32% -20% 75% 72% 52% 0.05 0.08 2009
FR 86% 52% 15% -31% -26% -22% 193% 46% 46% 0.05 0.08 2009
DE 78% 65% 12% -29% -29% -35% 54% 22% 127% 0.03 0.06 2008
GR 100 100% 95% -66% -67% -46% 1323% 714% -79% 0.02 0.00 2009
HU 100% 100% 70% -58% -58% -36% 209% 205% 3% 0.03 0.04 2009
IE 23% 21% 3% -26% -24% -13% 2% 6% 36% 0.06 0.08 2009
IT 92% 83% 36% -26% -26% -17% 123% 16% 12% 0.03 0.04 2009
NL 45% 45% 5% -31% -31% -26% 26% 24% -5% 0.03 0.03 2009
NO 86% 86% 5% -56% -56% -31% 38% 38% 164% 0.03 0.07 2009
PL 96% 96% 42% -55% -56% -41% 163% 122% 146% 0.02 0.04 2009
PT 88% 87% 47% -87% -86% -54% 42% 33% -42% 0.04 0.02 2009
RO 100% 100% 70% -66% -66% -62% 1755% 1755% 2542% 0.00 0.02 2009
SK 100% 100% 29% -82% -82% -61% 464% 464% 509% 0.01 0.05 2009
SL 56% 56% 11% -70% -70% -57% 87% 87% 178% 0.02 0.05 2009
ES 83% 82% 63% -40% -40% -24% 59% 47% -30% 0.04 0.03 2009
SE 94% 94% 56% -54% -54% -37% 242% 212% 38% 0.02 0.03 2009
CH 52% 51% 14% -37% -37% -28% 39% 32% 53% 0.03 0.04 2009
UK 98% 86% 58% -4% -5% -8% 228% 150% 80% 0.01 0.03 2008
EU 88% 77% 26% -37% -36% -27% 122% 63% 58% 0.03 0.04
Price changes per TD (total market) vary considerably across the different European countries included
in this study, ranging between (-62%) and 8%.

Human Growth Hormone (HGH)
HGH also known as somatropin, is a peptide hormone that stimulates growth, cell reproduction
and regeneration in humans. It is used to treat growth disorders in children and growth hormone
deficiency in adults.
HGH volume development
10000
Non Referenced Medicinal
Products: Norditropin, Saizen,
9000 NutropinAq, Zomacton, Maxomat*
8000
7000 Genotropin, Humatrope
TD per 100,000
6000
5000 Omnitrope
4000
3000
2000
1000
0
The average for EEA is not
2006 representative
2007 2008 2009 for any 2011
2010 individual
2012country
2013 which
2014 is illustrated
2015 2016 in the next section.
Source: QuintilesIMS MIDAS December 2016; Total volume development across all European countries included in the study *Maxomat has been discontinued
Summary of EMA information for approved indications for HGH products:
Indication
Classification Indication
SHOX -
Growth Short-Stature
Pediatric Adult failure due to SGA - Homebox-
Non- Growth Growth Chronic Renal Small for PWS - Idiopathic Containing
Reference Biosimilar reference Hormone Hormone Turner Insufficiency Gestational Prader-Willi Short Gene Noonan
Molecule Product product Product Product Deficiency Deficiency Syndrome (CRI) Age syndrome Stature Deficiency syndrome
Genotropin
Lonquex
Humatrope
Omnitrope
Somatropin Norditropin
Saizen
NutropinAq
Zomacton

HGH
Additional information about HGH
Subcutaneous injection is typically used to administer Human Growth Hormone treatment. The dosage
of administration should be individualised for each patient, with a weight-based regimen. The duration
of treatment, usually a period of several years, will depend on maximum achievable therapeutic
benefit.
countries:

AU 37% 17% 17% -17% -9% -9% 22% 54% 54% 0.04 0.05 2008
BE 28% 16% 16% -24% -20% -20% 48% 39% 39% 0.08 0.11 2009
BU 34% 34% 34% -30% -30% -30% -31% -32% -32% 0.02 0.02 2012
CZ 17% 7% 7% -23% -25% -25% 69% 68% 68% 0.08 0.13 2010
DK 97% 69% 69% -14% -15% -15% 109% -7% -7% 0.15 0.14 2011
FI 57% 20% 20% -48% -52% -52% 42% 70% 70% 0.06 0.10 2008
FR 34% 16% 16% -14% -11% -11% 42% 51% 51% 0.10 0.15 2007
DE 32% 15% 15% 7% 8% 8% 10% 36% 36% 0.06 0.08 2006
GR* 0% 0% 0% -9% -9% -9% -8% -8% -8% 0.00 0.00 2015
HU 13% 6% 6% -4% -3% -3% -9% 8% 8% 0.05 0.05 2012
IE 0% 0% 0% -11% 3% 3% 51% 54% 54% 0.05 0.07 2006
IT 29% 15% 15% -19% -15% -15% 62% 51% 51% 0.06 0.09 2007
NL 31% 17% 17% -38% -31% -31% 35% 46% 46% 0.08 0.12 2008
NO 29% 15% 15% -54% -37% -37% 57% 35% 35% 0.13 0.18 2011
PL 99% 99% 99% -41% -42% -42% 83% 82% 82% 0.04 0.08 2008
PT 13% 6% 6% -46% -28% -28% -1% -9% -9% 0.04 0.04 2014
RO 56% 25% 25% -17% -31% -31% 211% 152% 152% 0.02 0.06 2008
SK 0% 0% 0% -10% -9% -9% 15% 25% 25% 0.06 0.08 2013
SL 8% 4% 4% -24% -26% -26% 22% 17% 17% 0.06 0.07 2010
ES 30% 21% 21% -19% -19% -19% 46% 38% 38% 0.10 0.13 2007
SE 33% 20% 20% -34% -33% -33% -15% -7% -7% 0.15 0.14 2007
CH 19% 4% 4% -30% -22% -22% -8% 45% 45% 0.07 0.10 2010
UK 22% 11% 11% -25% -16% -16% 46% 79% 79% 0.04 0.07 2007
EU 39% 21% 21% -21% -15% -15% 41% 45% 45% 0.06 0.09
Prices per TD (total market) vary considerably across the different European countries studied, ranging
between (-52%) to 8%.

Anti-Tumour Necrosis Factor (Anti-TNF)
Anti-TNF drugs are a class of drugs that are used to treat inflammatory conditions such as Rheumatoid
Arthritis (RA), Ankylosing Spondylitis, Psoriatic Arthritis, Juvenile Arthritis, Crohn’s Disease, Ulcerative
Colitis, Psoriasis and Hidradinitis Suppurativa. These drugs are able to reduce inflammation and stop
disease progression.
TNF is a chemical produced by the immune system that causes inflammation in the body. In healthy
individuals, excess TNF in the blood is blocked naturally, but in those who have conditions like RA,
higher levels of TNF in the blood lead to more inflammation, joint destruction and persistent
symptoms. Anti-TNF agents can alter the disease’s effect on the body by controlling inflammation in
joints, gastrointestinal tract and skin.
Anti-TNF volume development
70000
Products: Cimzia, Humira, Simponi
60000

50000 Remicade, Enbrel
TD per 100,000
40000
Inflectra, Remsima, Flixabi, Benepali
30000
20000
10000
0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Additional information about Anti-TNF’s
There are currently biosimilars on the market for two Anti-TNF molecules in Europe, infliximab
and etanercept. The EMA approved the first infliximab biosimilars in September 2013, and the first
etanercept biosimilar in January 2016. The biosimilar share of molecule treatment days in the EU5
is reported below:
Biosimilar treatment day share vs Referenced

product (December 2016)
Country infliximab etanercept

UK 64.1% (22) 31.6% (10)
France 24.6% (22) 1.0% (3)
Germany 27.2% (23) 19.0% (10)
Italy 46.6% (22) 1.0% (3)
Spain 34.8% (23) 0.4% (3)
Source: QuintilesIMS MIDAS December 2016

Anti-TNF
Summary of EMA information for approved indications for Anti-TNF products:
Remicade
Remsima
Benepali
Inflectra
Simponi
Humira
Cimzia
Flixabi
Enbrel
Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Axial Spondyloarthritis, comprising:
Ankylosing Spondylitis (AS)
Axial Spondyloarthritis without
radiographic evidence of AS
Crohn's Disease
Paediatric Crohn's Disease
Ulcerative Colitis
Paediatric Ulcerative Colitis
Psoriasis
Paediatric Plaque Psoriasis
Hidradenitis Suppurativa*
Uveitis
*Hidradenitis Suppurativa includes both adults and adolescents from the age of 12 years. Adolescents do not have a separate
pediatric indication.
Indications have been added over time expanding the potential patient population.
Summary of EMA information for administration frequency details for Anti-TNF products:
Classification Frequency of Route of administartion

administration
Reference Biosimilar Non- reference Non-accessible
Molecule Product product Product Product Product Subcutaneous Intravenous
Remsima every 8 weeks
Inflectra every 8 weeks
INFLIXIMAB every 8 weeks
Remicade
Flixabi every 8 weeks
Enbrel once or twice weekly
ETANERCEPT Benepali once weekly
ADALIMUMAB Humira every 2 weeks
CERTOLIZUMAB PEGOL Cimzia every 4 weeks
GOLIMUMAB Simponi monthly

Anti-TNF
countries:

AU 23% 23% 17% -17% -17% -12% 29% 29% 33% 0.17 0.22 2015
BE 5% 5% 3% -24% -24% -15% 19% 19% 17% 0.94 1.10 2015
BU 48% 48% 17% -41% -41% -23% 163% 163% 190% 0.10 0.29 2014
CZ 25% 25% 17% -14% -14% -13% 51% 51% 59% 0.24 0.38 2013
DK 90% 90% 60% -35% -35% -24% 45% 45% 28% 0.91 1.17 2015
FI 61% 61% 36% -24% -24% -18% 47% 47% 54% 0.64 0.99 2013
FR 14% 14% 8% -16% -16% -12% 22% 22% 27% 0.62 0.78 2015
DE 17% 17% 9% -6% -6% -3% 18% 18% 22% 0.51 0.62 2015
GR* 0.00 0.01
HU 26% 26% 14% -6% -6% -3% -6% -6% -5% 0.32 0.30 2014
IE 5% 5% 3% -10% -10% -6% 43% 43% 48% 1.00 1.48 2014
IT 20% 20% 11% -6% -6% -4% 4% 4% 14% 0.36 0.41 2015
NL 32% 32% 20% -8% -8% -6% 11% 11% 8% 1.00 1.08 2015
NO 82% 82% 53% -48% -48% -32% 48% 48% 56% 1.08 1.68 2013
PL 24% 24% 16% -13% -13% -11% -14% -14% 7% 0.03 0.03 2014
PT 18% 18% 12% -20% -20% -13% 56% 56% 63% 0.26 0.43 2013
RO 11% 11% 7% -10% -10% -9% -9% -9% 12% 0.20 0.22 2014
SK 6% 6% 4% -28% -28% -19% 92% 92% 93% 0.49 0.95 2014
SL 14% 14% 7% -19% -19% -11% 26% 26% 24% 0.47 0.58 2015
ES 19% 19% 11% -20% -20% -9% 16% 16% 21% 0.49 0.60 2015
SE 29% 29% 12% -16% -16% -39% 18% 18% 74% 0.94 1.64 2015
CH 2% 2% 1% -2% -2% -4% 9% 9% 10% 0.84 0.92 2016
UK 33% 33% 16% -6% -6% -2% 12% 12% 20% 0.62 0.74 2015
EU 24% 24% 13% -13% -13% -10% 19% 19% 26% 0.49 0.61
Prices per TD (total market) have been reduced in all markets but to a different degree (-2) to (-39).
The Anti-TNF market is unique as it has two referenced products with different biosimilar molecules.
The market shares and price/volume evolution figures refer to the total Anti-TNF market, therefore
include all products within each category. This means, for example, in markets where only infliximab
has launched, the “biosimilar vs referenced product” market share will still represent the biosimilar
market share of all the biosimilars and referenced products on the market (including Enbrel).

Fertility (Follitropin alfa)
Gonadotropin preparations are drugs that mimic the physiological effects of gonadotropins, used
therapeutically primarily as fertility medication for ovarian hyperstimulation and reversal of an
ovulation.
For the purpose of this report, only Follicle-Stimulating Hormones (FSH) and Luteinizing Hormone
(LH) preparations were considered.
Fertility volume development
Non-accessible Medicinal Products:

6000 Menogon, Menopur, Menotrophin,
Meriofert, Mensinorm, Bravelle,
Fertinorm, Fostimon, Fostimonkit,
5000 Fostipur, Metrodin, Urofollitropin

4000
Gonal-F
TD per 100,000
3000 Non Referenced Medicinal Products:

Puregon, Pergoveris, Elonva, Luveris,
Ovitrelle
2000

1000
Bemfola & Ovaleap
0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Summary of EMA information for approved indications for Fertility products
Classification Indications Frequency Route
Iintramuscular
Non-accessible
Subcutaneous
Non-reference
Intravenous
Reference
Reproductive
Biosimilar
product
Ovulation Techniques,
Molecule Product Infertility Hypogonadism Anovulation Induction Assisted
Gonal-F Daily
Follitropin alfa Bemfola Daily
Ovaleap Daily
Follitropin alfa/lutropin alfa Pergoveris Daily
Follitropin beta Puregon Patient specific
Corifollitropin alfa Elonva Patient specific
Lutropin alfa Luveris Daily

Menogon Daily
FOLLICLE-STIMULATING Menopur Daily
HORMONE/LUTEINISING Menotrophin Daily
HORMONE Meriofert Daily
Mensinorm Daily
Bravelle Daily
Fertinorm Daily
UROFOLLITROPIN Fostimon Daily
Fostimonkit Daily
Fostipur Daily
Metrodin Daily

Fertility
Additional information about fertility medicines:
countries:

AU 3% 1% 1% 1% -1% 16% 614% 170% 69% 0.01 0.02 2014
BE 17% 11% 4% -1% -1% -9% 12% 8% 22% 0.04 0.05 2015
BU 32% 7% 3% -6% -3% 17% 131% -10% -27% 0.01 0.01 2016
CZ 6% 4% 2% -16% -15% -5% 1% 10% -5% 0.05 0.05 2015
DK 16% 11% 5% -21% -20% -24% 43% 20% 19% 0.10 0.12 2014
FI 24% 16% 8% -12% -10% -6% 76% 8% 6% 0.04 0.05 2014
FR 13% 9% 5% -2% -2% -4% 18% 3% 9% 0.09 0.10 2015
DE 19% 11% 6% -4% -3% 0% 48% 28% 21% 0.04 0.05 2014
GR* 14% 11% 4% -5% -3% -3% 29% 16% 23% 0.02 0.03 2016
HU 15% 13% 9% -3% -3% 1% 46% 44% 35% 0.04 0.06 2015
IE 0% 0% 0% -3% -3% -1% 14% 7% 6% 0.10 0.10 2016
IT 2% 2% 1% 0% 0% -1% -6% -7% -1% 0.07 0.07 2015
NL 0% 0% 0% 0% 0% 1% 5% 4% 3% 0.07 0.07 2016
NO 35% 21% 9% -4% -3% -6% 43% 18% 23% 0.06 0.08 2014
PL 7% 2% 1% 27% 6% 4% -12% 65% 45% 0.02 0.03 2015
PT 14% 7% 4% -13% -8% 1% 14% 10% 9% 0.03 0.04 2015
RO 0.00 0.02
SK 3% 3% 1% -4% -3% 13% 30% 17% -4% 0.02 0.02 2016
SL 0% 0% 0% 0% 1% -1% 7% 3% 2% 0.06 0.06 2015
ES 21% 13% 6% -26% -17% -14% -1% -10% -7% 0.09 0.09 2015
SE 18% 15% 6% -18% -18% -10% 42% 14% 11% 0.09 0.09 2014
CH 0.01 0.04
UK 18% 17% 6% 0% 0% 1% 21% 20% 15% 0.02 0.02 2015
EU 12% 8% 4% -6% -5% -4% 16% 8% 10% 0.05 0.06
Prices per TD (total market) have been reduced in all markets but to a different degree (-24%) to 17%.

Insulins
Recombinant human insulin is a form of insulin made from recombinant DNA that is identical to
human insulin; used to treat diabetics who are allergic to preparations made from beef or pork
insulin.
Insulins volume development
800000
Non-accessible Medicinal Products:
all fast acting and intermediate-acting
700000 product
600000 Non-referenced Medicinal Products:

all remaining long acting products
500000
TD per 100,000

400000
Lantus
300000 Biosimilar Medicinal Products:

Abasaglar
200000
100000
0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Additional information about Insulins
Insulin preparations differ mainly by their kinetic/pharmacodynamic profiles. They are usually
classified as rapid- (faster acting than soluble human insulin), short- (e.g. soluble human insulin),
intermediate- (e.g. human isophane insulin = NPH insulin), and long-acting preparations (insulins
with action profiles significantly longer than NPH insulin), and are used alone or as free mixtures or
premixed preparations of rapid/short-acting insulin and intermediate/long-acting (biphasic) insulin
in various proportions.
The EMA authorised Lusduna, the second insulin glargine biosimilar to be authorised in Europe, in
January 2017. This product was not included in the study.

Insulins
Summary of EMA information for approved indications for Insulin products
Classification Indications Frequency* Mode of Route

action
Non-accessible
Non-reference
Subcutaneous
Intravenous
Reference
Biosimilar
product
Diabetes
Molecule Product Mellitus
Abasaglar Daily Long-acting
Insulin Glargine (previously Abasria)
Lantus Daily Long-acting
Insulin Degludec Tresiba Daily Long-acting
Insulin Detemir Levemir Twice a day Long-acting
Insulin Degludec / Daily Long-acting
Liraglutide Xultophy
Novorapid Twice / 5x a day Short-acting

Insulin Aspart
Novomix Twice / 5x a day Short-acting
Insulin Degludec /
Insulin Aspart Ryzodeg Daily Short-acting
Insulin Glulisine Apidra Twice / 5x a day Short-acting
Actraphane Once / twice a day Short-acting
Actrapid Twice / 5x a day Short-acting
Insulatard Once / twice a day Long-acting
Insuman Once / twice a day Short-acting
Insulin Human Mixtard Once / twice a day Short-acting
Monotard Once / twice a day Intermediate-acting
Humalin Once / twice a day Intermediate-acting
Protaphane Once / twice a day Long-acting
Ultratard Once / twice a day Long-acting
Liprolog Twice / 5x a day Short-acting
Insulin Lispro
Humalog Twice daily Short-acting
* Regular insulin is a short-acting insulin and is generally injected subcutaneously 2-5 times daily within 30-60 minutes before a meal.
* In conventional regimen the total daily insulin dose is administered as a mixture of rapid/short-acting and intermediate-acting insulins in 1-2 injections.
* In intensive regimen the total daily dose is administered as 3 or more injections or by continuous subcutaneous infusion to cover basal and
Regular insulin
* pre-meal bolus is requirements.
*insulin a short-acting insulin and is generally injected subcutaneously 2-5 times daily within
30-60 minutes before a meal.
In conventional regimen the total daily insulin dose is administered as a mixture of rapid/short-acting
and intermediate-acting insulins in 1-2 injections. In intensive regimen the total daily dose is
administered as 3 or more injections or by continuous subcutaneous infusion to cover basal and pre-meal
bolus insulin requirements.

Insulins
countries:

AU 0% 0% 0% 0% 0% 0% 0% 0% 0% 5.65 5.65
BE 0% 0% 0% -6% -5% 0% 19% 15% 5% 6.54 6.87 2016
BU 2% 1% 0% -7% -3% 3% 49% 47% 9% 5.73 6.24 2015
CZ 10% 6% 2% -5% -4% 5% 48% 40% 13% 7.70 8.72 2015
DK 3% 2% 1% -0% 2% 3% 43% 32% 6% 6.66 7.05 2015
FI 1% 1% 0% -36% -26% -18% 74% 39% 23% 11.58 14.28 2015
FR 0% 0% 0% -12% -9% -5% 7% 5% 3% 6.22 6.43 2016
DE 4% 3% 1% -1% 0% 3% 38% 22% 2% 11.69 11.88 2015
GR* 5% 4% 2% -2% 4% 5% 13% 15% 3% 6.89 7.09 2016
HU 5% 3% 1% -1% 16% 11% 29% 27% 7% 9.14 9.74 2015
IE 0% 0% 0% -9% -5% -3% 5% 5% 3% 4.86 5.02 2016
IT 7% 5% 2% -5% 2% 2% 1% 4% 0% 5.64 5.65 2016
NL 1% 1% 0% -3% 3% 5% 7% 9% 0% 9.12 9.06 2015
NO 1% 1% 0% 15% 18% 15% 24% 17% 5% 6.95 7.26 2015
PL 23% 19% 1% -21% -18% 0% 95% 76% 2% 6.69 6.82 2015
PT 1% 0% 0% -6% -4% 0% 14% 13% 7% 5.63 6.02 2016
RO 3% 2% 1% 0% -2% 0% 21% 19% 6% 4.98 5.30 2016
SK 26% 22% 6% -10% -8% 3% 94% 67% 18% 651 7.65 2015
SL 3% 2% 0% -8% -2% 0% 4% 5% 2% 8.55 8.72 2016
ES 5% 4% 2% -12% -7% -2% 18% 17% 6% 6.97 7.42 2015
SE 4% 2% 1% -1% 4% 2% 9% 13% 4% 9.97 10.35 2015
CH 0% 0% 0% -10% 18% 14% -4% 10% 3% 4.63 4.76 2015
UK 1% 1% 0% -1% 1% 0% 3% 5% 6% 7.48 7.90 2015
EU 4% 3% 1% -7% -3% 1% 19% 15% 4% 7.53 7.82

Reading Guide
This example has been developed as a simplified guide to read the report that has a broad set of Key
Performance Indicators for multiple countries. EPO in Austria is used as the example.
Volume development
The chart Epoetin Volume Development shows volume development over time across all the European
countries included in the study. Volume is expressed in (WHO) DDDs as a proxy to be able to compare
different products.
The blue part of the chart shows the volume share of Biosimilar Medicinal Products (listed) which is
currently at 25%. The yellow part shows volume share of Referenced Medicinal Products to the
approved Biosimilar products which is currently at 15%.
The Non-Referenced Competing Medicinal Products (green part of the chart) are other products with
a largely similar profile to the Referenced Products, but have not been referenced. This category was
affected by biosimilar entrance, which resulted in a loss of market share from 32% in 2007 to 16% in
2016. The Non–accessible market (red part of the chart) are the Pegylated (long-acting) products, with
45% market share.
Epoetin volume development
60000
Products: Aranesp, Mircera
50000
Non Referenced Medicinal Products:
NeoRecormon, Eporatio, Dynepo*
40000
TD per 100,000

30000 Erypo, Epopen, Epopen
20000
Abseamed, Binocrit, Epoetin Alfa-
Hexal, Retacrit, Silapo
10000
0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Source: QuintilesIMS MIDAS December 2016; Total volume development across all European countries included in the study *Dynepo has been withdrawn by the EMA.

Reading Guide
Approved indications
The table Summary of EMA information for approved indications for Epoetin products shows that the
Biosimilar Medicinal Products receive the same indications as the Referenced Medicinal Products.
It also shows that not all products are approved for all indications. However, indications are very
different in patient populations; this difference can be effective in limiting patient potential.
Frequency of injecting can also vary and the implication of this might vary with patient type.
Summary of EMA information for approved indications for Epoetin products:
Patient
type Frequency* Route**
Reduction of
Reference product
allogenic
Non-accessible
Subcutaneous
Non-reference
Anaemia for Preventing transfusion
Intravenous
Paedriatic
Biosimilar
Anaemia for patients with Anaemia in Autologuos exposure in

Chemotherapy Chronic Kidney premature Blood Orthopedic
Adult
Molecule Product patients Disease babies Transfusion surgery
Epopen 3x a week
Erypo 3x a week
3x a week
Epoetin alfa Epogen
3x a week
Abseamed 3x a week
Epoetin Alfa Hexal 3x a week
3x a week
Binocrit
Retacrit
Epoetin zeta 3x a week
Silapo
Epoetin beta NeoRecormon 3x a week
Epoetin theta Eporatio 3x a week
Methoxy
polyethlene Mircera Every 2 weeks
glycol-epotein
beta
Darbepoetin alfa Aranesp Weekly
*Anaemia for patients with Chronic kidney disease ** Subcutaneous injection is typically used for chemotherapy patients. Intravenous injection
is typically used for patients with kidney problems and for patients who are going to donate
their own blood.

Reading Guide
Selected KPIs
The first set of indicators is the Market share TD 2016 calculated in treatments days. In Austria,
Biosimilars represent 76% of Biosimilar + Referenced Products (which includes all the biosimilars
and all the referenced products on the market for a therapy area). If the Non-Referenced Medicinal
Product is also included (total accessible market), the share of Biosimilar Medicinal Product is 25%.
Looking at the Biosimilar Medicinal Product versus total market, the market share is 16%.

AU 76% 25% 16% -36% -37% -26% -29% -8% -26% 0.95 0.70 2008
The second set of indicators, Price per TD (2016/Year before biosimilar entrance), shows price
development per treatment day (DDD) comparing 2016 price with prices in the year before the first
Epoetin Biosimilar Medicinal Product was launched (which is 2008 in the case of Austria). The
volume-weighted average price in 2016 vs. 2007 has fallen 36% for the Biosimilar Medicinal Product
and Referenced Product, 37% for Biosimilar Accessible Market and 26% for the total market. This
data illustrates that the competitive response, or the price regulators response is to lower prices on
other products in the market, as competition intensifies.

AU 76% 25% 16% -36% -37% -26% -29% -8% -26% 0.95 0.70 2008
The third set of indicators, Volume TD (2016/Year before biosimilar entrance), shows the volume
development in treatment days (DDDs) comparing 2016 versus the year before the first Epoeitin
Biosimilar Medicinal Product was launched (which is 2008 in the case of Austria).While the Biosimilar
and the Referenced Product volume has decreased 29%; the full accessible market volume decreased
8% and the total market volume decreased 26%.

AU 76% 25% 16% -36% -37% -26% -29% -8% -26% 0.95 0.70 2008

Reading Guide
The last set of indicators, TD per capita (Year before biosimilar entrance) and TD per capita 2016,
show the usage per capita before the entrance of biosimilars (which is 0.95 in Austria), and the usage
per capita of the total market in 2016 (which is 0.7 in Austria). The year with the First recorded sales
of Biosimilar in Austria is 2008. In classes where there are multiple biosimilars, this will reflect the
first recorded sales of the first biosimilar which entered the market.

AU 76% 25% 16% -36% -37% -26% -29% -8% -26% 0.95 0.70 2008

Appendices
1 EMA list of approved Biosimilars (April 2017)
Active Authorisation
Medicine Name Substance Atc code Marketing Authorisation Holder date
Abasaglar (previously Abasria) insulin glargine A10AE04 Eli Lilly Regional Operations GmbH 09/09/2014
Abseamed epoetin alfa B03XA01 Medice Arzneimittel Pütter GmbH & Co. KG 28/08/2007
Accofil filgrastim L03AA02 Accord Healthcare Ltd 18/09/2014
Amgevita adalimumab L04AB04 Amgen Europe B.V. 22/03/2017
Bemfola follitropin alfa G03GA05 Gedeon Richter Plc. 27/03/2014
Benepali etanercept L04AB01 Samsung Bioepis UK Limited (SBUK) 14/01/2016
Binocrit epoetin alfa B03XA01 Sandoz GmbH 28/08/2007
Epoetin Alfa Hexal epoetin alfa B03XA01 Hexal AG 28/08/2007
Filgrastim Hexal filgrastim L03AA02 Hexal AG 06/02/2009
Flixabi infliximab L04AB02 Samsung Bioepis UK Limited (SBUK) 26/05/2016
Grastofil filgrastim L03AA02 Apotex Europe BV 18/10/2013
Inflectra infliximab L04AB02 Hospira UK Limited 10/09/2013
Inhixa enoxaparin sodium B01AB05 Techdow Europe AB 15/09/2016
Lusduna insulin glargine A10AE04 Merck Sharp & Dohme Limited 04/01/2017
Movymia teriparatide H05AA02 STADA Arzneimittel AG 11/01/2017
Nivestim filgrastim L03AA02 Hospira UK Ltd 08/06/2010
Omnitrope somatropin H01AC01 Sandoz GmbH 12/04/2006
Ovaleap follitropin alfa G03GA05 Teva Pharma B.V. 27/09/2013
Ratiograstim filgrastim L03AA02 Ratiopharm GmbH 15/09/2008
Remsima infliximab L04AB02 Celltrion Healthcare Hungary Kft. 10/09/2013
Retacrit epoetin zeta B03XA01 Hospira UK Limited 18/12/2007
Silapo epoetin zeta B03XA01 Stada Arzneimittel AG 18/12/2007
Solymbic adalimumab L04AB04 Amgen Europe B.V. 22/03/2017
Terrosa teriparatide H05AA02 Gedeon Richter Plc. 04/01/2017
Tevagrastim filgrastim L03AA02 Teva GmbH 15/09/2008
Thorinane enoxaparin sodium B01AB05 Pharmathen S.A. 15/09/2016
Truxima rituximab L01XC02 Celltrion Healthcare Hungary Kft. 17/02/2017
Zarzio filgrastim L03AA02 Sandoz GmbH 06/02/2009

Appendices
A list of Biosimilars under review by EMA (April 2017)
Number of Originator Originator

Common name Therapeutic area applications product company
Adalimumab Immunosuppressant 2 Humira AbbVie Ltd
Bevacizumab Antineoplastic 2 Avastin Roche

medicines
Etanercept Immunosuppressant 1 Enbrel Amgen
Insulin glargine Diabetes 1 Lantus Sanofi-Aventis
Insulin lispro Medicines used in 1 Humalog Eli Lilly

diabetes
Neulasta
Pegfilgrastim Immunostimulants 2 Amgen
Antineoplastic
Rituximab medicines 5 MabThera Roche
Antineoplastic
Trastuzumab medicines 4 Herceptin Roche
2 Methodology
• The volumes have been converted by QuintilesIMS into daily doses using WHO DDDs. Consumption
measures are therefore not adjusted for clinical practice guidelines, patient characteristics,
indications for which the molecule is used, or other factors which may result in different volumes
utilised on a per patient treatment day basis.
• Volume share is calculated as the volume in DDD versus the relevant market (reference market,
accessible market, total market).
• Prices are calculated as a volume weighted ex-manufacturing price.
• Price evolution is calculated as the present price for the relevant market versus the price for the
same relevant market before the introduction of biosimilars in the country.
• Volume evolution is calculated as the present total volume versus the total volume before the
introduction of biosimilars in the country.

Appendices
Methodology
Biosimilar vs
TD Biosimilars as % of TD Reference products in 2016
Reference product
Biosimilar vs
Market share TD Accessible market
TD Biosimilars as % of TD Accessible market in 2016
Biosimilar vs
TD Biosimilars as % of TD Total market in 2016
Total market
Biosimilar and Δ in Price per TD for Biosimilar Reference products 2016/the year
Reference product before biosimilar entrance
Biosimilar Δ in Price per TD for Biosimilar Accessible market 2016/the year

Price per TD Accessible market before biosimilar entrance
Δ in Price per TD for Total market 2016/the year before biosimilar

Total market
entrance
Biosimilar and Δ in TD for Biosimilars and Reference products 2016/the year

Reference product before biosimilar entrance
Biosimilar Δ in TD for Biosimilar Accessible market 2016/the year before

Volume TD Accessible market biosimilar entrance
Total market Δ in TD for Total market 2016/the year before biosimilar entrance
TD per capita No. Of Treatment Days per capita in 2016
No. Of Treatment Days per capita the year before

TD per capita year before biosimilar entrance biosimilars entered the market
First recorded sales The year first sales of biosimilar were recorded
3 QuintilesIMS source of volume data
Volume information is based on channel audits for retail and non-retail channels, covering the
majority of volume consumed in a country market, though may exclude some direct sales made from
the manufacturer to dispensing locations. QuintilesIMS source of volume data collection route and
sample varies by country; data can be collected at various points within the pharmaceutical supply
chain.
Note: Points of collection
Sell-in data represents the supply of products from wholesalers to pharmacies.

Sell-out data represents the demand for products from the pharmacies to patients.
Hospital consumption data measures dispensing of products by hospital pharmacies within the
hospital wards.
The table below is a matrix to identify these points of collection by country.
AU BE BU CZ DK FI FR DE GR HU IE IT NL NO PL PT RO SK SL ES SE CH UK
Retail In In In In In In Out Out Out In In In In In In In Out In Out Out In Out
Hospital C C In In In In C C In In C In In In C In In C In In C
Combined In

Appendices
4 QuintilesIMS source of price data
Sales data is collected in terms of the number of Pack Units sold and are then multiplied by the Pack
Price to produce the sales values. Pricing information is based on a variety of sources including list
price, wholesaler transactions, government price list and industry publications, but does not reflect
rebates and discounts which in some countries and channels may be significant. Country volumes
may also be impacted by unknown parallel exports or imports which cannot be identified or adjusted
for. Inclusion of VAT and taxes varies per country.
The table below shows the price source reference within each country included in the study:
EU Geography
Country Sector (Data Type) Price Source

Austria AU HOSPITAL (CONSUMPTION),RETAIL (SELL-IN) Hospital & Retail - List price - Arzneimittelverzeichnis or Taxe (Apotheker-Verlag)
Hospital - List price - Association Général de l'Industrie du Médicament (AGIM),
Belgium BE HOSPITAL (CONSUMPTION),RETAIL (SELL-IN) Retail - List price - Association Pharmaceutique Belge (APB)
Bulgaria BU HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - Average invoiced pack price
Czech Rep. CZ HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - Average invoiced pack price
Denmark DK RETAIL (SELL-IN),HOSPITAL (SELL-IN) Hospital & Retail - Average invoiced pack price
Finland FI HOSPITAL (SELL-IN),RETAIL (SELL-IN) List price - Wholesalers, based on official published prices of Finnish Pharmacy Association
Hospital - List price - Journal Officiel, manufacturer hospital price lists,
France FR HOSPITAL (CONSUMPTION),RETAIL (SELL-OUT) Retail - List price - Journal Officiel, wholesaler catalogues, average transaction prices
Hospital - Estimated transaction price reflecting the average level of rebates and discounts,
Germany DE HOSPITAL (CONSUMPTION),RETAIL (SELL-OUT) Pharmascope - List price - ABDATA (Pharmacist Association), sourced from IFA (German Health Institute)
Greece GR RETAIL (SELL-OUT) Retail - List price - Ministry of Development
Hungary HU HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - List price - National Health Fund, National Institute of Pharmacy
Ireland IE HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - List price - Irish prescription drug
DPC (CONSUMPTION),HOSPITAL (CONSUMPTION), DPC & Retail - List price - CFO - Farmadati, Gazzetta Ufficiale della Repubblica Italiana,
Italy IT Hospital - List price - 45% public level retail list price
RETAIL (SELL-IN)
Netherlands NL HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - List price - Wholesaler price list
Norway NO HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - Average invoiced pack price
Poland PL HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - Average invoiced pack price
Hospital - Average invoiced pack price,
Portugal PT HOSPITAL (CONSUMPTION),RETAIL (SELL-IN) Retail - List price - Manufacturer published price list
Hospital - Average invoiced pack price,
Romania RO HOSPITAL (SELL-IN),RETAIL (SELL-OUT) Retail - Canamed, average transaction price if no Canamed Price
Slovakia SK HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - Average invoiced pack price
Slovenia SL COMBINED (SELL-IN) Hospital & Retail - Average invoiced pack price
Spain ES HOSPITAL (CONSUMPTION), RETAIL (SELL-OUT) Hospital & Retail - List price - Manufacturer price list, Base de Datos del Medicamento (BOT)
Hospital & Retail - List price - Apoteket AB, The Dental and Pharmaceutical Benefits Agency,
Sweden SE RETAIL (SELL-OUT),HOSPITAL (SELL-IN) The Drug Benefit Board, The LFN
Switzerland CH HOSPITAL (SELL-IN),RETAIL (SELL-IN) Hospital & Retail - List price - Wholesalers, manufacturers
UK UK HOSPITAL (CONSUMPTION),RETAIL (SELL-OUT) Hospital & Retail - List price - Chemist and Druggist, Drug Tariff

United Kingdom Global Supplier Service and
QuintilesIMS
Association Relations
210 Pentonville Road Per Troein, VP [email protected]
London N1 9JY Ramya Logendra, Senior Consultant [email protected]
United Kingdom Neelam Patel, Consultant [email protected]
About QuintilesIMS
QunitilesIMS is a leading global information and technology services company providing clients in the healthcare
industry with comprehensive solutions to measure and improve their performance. End-to-end proprietary
applications and configurable solutions connect 10+ petabytes of complex healthcare data through the IMS OneTM
cloud-based master data management platform, providing comprehensive insights into diseases, treatments,
costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge
across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical,
consumer health and medical device manufacturers and distributors, providers, payers, government agencies,
policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, QunitilesIMS uses anonymous healthcare data to deliver
critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment
needs and understand the effectiveness and value of pharmaceutical products in improving overall health
outcomes. Additional information is available at www.imshealth.com.
©2017 QuintilesIMS. All rights reserved.

Trademarks are registered in the United States and in various other countries.

IMS Biosimilar 2017 - V9 PDF

Uploaded by

Copyright:

Available Formats

IMS Biosimilar 2017 - V9 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

IMS Biosimilar 2017 - V9 PDF

Uploaded by

Copyright:

Available Formats

May 2017

The Impact of Biosimilar

The Impact of Biosimilar Competition in Europe Page 2

The Impact of Biosimilar Competition in Europe Page 1

The Impact of Biosimilar Competition in Europe Page 2

Portugal -66% Romania -62% Slovakia -53% Slovakia -61%

Slovakia -53% Slovakia -61% Norway -51% Slovenia -57%

Norway -51% Slovenia -57% HGH Anti-TNF

HGH Anti-TNF Finland -52% Sweden -39%

The Impact of Biosimilar Competition in Europe Page 3

The Impact of Biosimilar Competition in Europe Page 4

The Impact of Biosimilar Competition in Europe Page 5

Biosimilar Market share TD (2016)

3. There is a first to market advantage in biosimilar markets

Price per Volume Price per Volume

The Impact of Biosimilar Competition in Europe Page 7

The Impact of Biosimilar Competition in Europe Page 8

Epoetin volume development

Referenced Medicinal Products:

Anaemia for Preventing transfusion

Anaemia for patients with Anaemia in Autologuos exposure in

Molecule Product patients Disease babies Transfusion surgery

Epoetin theta Eporatio 3x a week

The Impact of Biosimilar Competition in Europe Page 9

Additional information about Epoetin

Price per TD (2015/the year before Volume TD (2015/the year before

The Impact of Biosimilar Competition in Europe Page 10

G-CSF volume development

Non-accessible Market Medicinal

4000 Non-referenced Medicinal Products:

1500 Biosimilar Medicinal Products:

Summary of EMA information for approved indications for G-CSF products

The Impact of Biosimilar Competition in Europe Page 11

Additional information about G-CSF

Price per TD (2016/the year before Volume TD (2016/the year before

The Impact of Biosimilar Competition in Europe Page 12

HGH volume development

Summary of EMA information for approved indications for HGH products:

The Impact of Biosimilar Competition in Europe Page 13

Additional information about HGH

Price per TD (2016/the year before Volume TD (2016/the year before

The Impact of Biosimilar Competition in Europe Page 14

Anti-TNF volume development

Referenced Medicinal Products:

Additional information about Anti-TNF’s

Biosimilar treatment day share vs Referenced

Country infliximab etanercept

The Impact of Biosimilar Competition in Europe Page 15

Summary of EMA information for approved indications for Anti-TNF products:

Classification Frequency of Route of administartion

The Impact of Biosimilar Competition in Europe Page 16

Price per TD (2016/the year before Volume TD (2016/the year before

The Impact of Biosimilar Competition in Europe Page 17

Fertility volume development

Non-accessible Medicinal Products:

Referenced Medicinal Products:

3000 Non Referenced Medicinal Products:

Biosimilar Medicinal Products:

Summary of EMA information for approved indications for Fertility products